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Myocardial angiogenesis induction with vas-
cular growth factors constitutes a potential strat-
egy for patients whose coronary artery disease is
refractory to conventional treatment. The impor-
tance of angiogenesis in bone formation has led to
the development of growth factors derived from
bovine bone protein. 
Twelve pigs (mean weight, 73 ± 3 kg) were cho-
sen for the study. In the first group (n = 6, growth
factor group) five 100 µg boluses of growth factors
derived from bovine bone protein, diluted in Povi-
done 5%, were injected in the lateral wall of the
left ventricle. In the second group (n = 6, control
group), the same operation was performed but
only the diluting agent was injected. All the ani-
mals were sacrificed after 28 days and the vascular
density of the left lateral wall (expressed as the
number of vascular structures per mm2) as well as
the area of blood vessel profiles per myocardial
area analysed were determined histologically with
a computerised system. 
The growth factor group had a capillary den-
sity which was significantly higher than that of the
control group: 12.6 ± 0.9/mm2 vs 4.8 ± 0.5/mm2
(p <0.01). The same holds true for the arteriolar
density: 1 ± 0.2/mm2 vs 0.3 ± 0.1/mm2 (p <0.01).
The surface ratios of blood vessel profiles per myo-
cardial area were 4900 ± 800 µm2/mm2 and 1550 
± 400 µm2/mm2 (p <0.01) respectively
In this experimental model, bovine bone pro-
tein derived growth factors induce a significant
neovascularisation in healthy myocardium, and
appear therefore as promising candidates for
therapeutic angiogenesis. 
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Summary
Introduction
There is a growing number of patients who
suffer from debilitating angina because of a coro-
nary artery disease unresponsive to medication and
who are neither candidates for percutaneous coro-
nary angioplasty nor for coronary artery bypass
surgery because the atherosclerotic lesions are too
diffuse. Therefore alternative methods of treat-
ment are currently under investigation. Among
them, therapeutic angiogenesis appears to be a
promising tool. Compensatory angiogenesis – the
development of functional collaterals induced by
specific growth factors – is a natural response to re-
gional ischaemia. However, this process is rather
slow and usually insufficiently compensates the
ischaemia induced by an acute coronary artery
occlusion. It appears therefore logical to bring
growth factors directly to the ischaemic territories
which are inaccessible to conventional treatment
in order to amplify this compensatory mechanism. 
The important role played by angiogenesis in
bone formation [1, 2] gave the impetus to the de-
velopment of growth factors derived from bone
protein. This study was designed to analyse the an-
giogenic effects of these growth factors on healthy
myocardium in a pig model. 
Growth factor mixture
Bone protein (Provasc, Sulzer Carbomedics, Austin,
Texas, USA) is the result of the isolation of proteins from
bovine (< 2 years old, USA) femurs, marrow-free, in the
range of 10 to 100 kDa. Based on ELISA assays some
angiogenic factors have been detected such as FGF
(fibroblast growth factor) and TGF-β (transforming
growth factor-β). It is hypothesised that the mechanism of
action is due to the synergy between multiple factors, some
of which are not yet characterised. The growth factor
mixture is diluted in 5% Povidone to a concentration of
1 mg/ml.
Animal preparation
The study was performed in 12 pigs (mean weight 73
± 3 kg). The animals were premedicated with Ketamine
(10 mg/kg) and Atropine (2 mg) injected intramusculary.
Vascular access was established through a vein of the ear.
After induction with sodium thiopentone (5 mg/kg)
through this venous line, the animals were intubated and
anaesthesia was maintained by intravenous administration
of sodium thiopentone as needed. Three ECG leads were
installed. A left lateral cervicotomy was performed to pro-
vide vascular access. A left lateral thoracotomy was per-
formed through the fifth intercostal space. The peri-
cardium was opened and reflected to form a cradle for sus-
pending the heart.
Experimental protocol
The animals were randomised into two groups. In the
first group (growth factor group, n = 6), five 100 µg bo-
luses of bovine bone derived growth factor mixture were
injected, 1 cm apart, in the lateral wall of the left ventri-
cle. The injection sites were marked with a non-resorbable
suture in order to localise them later for histology. In the
second group (control group, n = 6), the same protocol was
performed but Povidone solution without growth factor
was injected. At the end of the operation, the thoracotomy
was closed on a chest tube which was removed after wean-
ing from the ventilator.
Control operation
After a month, the animals were sacrificed with an in-
travenous bolus injection of saturated potassium chloride
and the hearts were rapidly excised for fixation in buffered
formaldehyde (4%) for histology. 
Histology and morphometry
The lateral wall of the left ventricle was excised and
divided into two perpendicular to the axis of injection, at
the mid-level of the myocardial thickness. Serial sections
were stained with haematoxylin and eosin. The vascular
endothelium was stained immunohistochemically with
antifactor VIII (Dako, Glostrup, Denmark) using the
Avidin-Biotin-Complex (ABC) Peroxidase method. The
structures stained with factor VIII were counted with an
image analysis system (Image Pro 3.0, Media Cybernetics,
MD, USA) and expressed as the number of structures per
mm2. The area of blood vessel profiles was calculated in
µm2 and expressed per mm2 of myocardial area examined
histologically. For this analysis, three fields of 10 mm2 were
randomly selected within the marked areas of injection.
Statistics
The results of morphological analysis were given as
mean plus or minus standard deviation. The vascular den-
sities of the different areas were compared using a t test.
Values were considered to differ significantly if p <0.05.
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Methods
Results
The growth factor group exhibited a vascular
density which was significantly higher than that of
the control group: 13.6 ± 0.5/mm2 vs 5.1 ±
0.2/mm2 (p <0.01). When capillary and arteriolar
structures were counted separately, the differences
persisted: 12.6 ± 0.9/mm2 vs 4.8 ± 0.5/mm2
(p <0.01) for the capillary density and 1 ± 0.2/mm2
vs 0.3 ± 0.1/mm2 (p <0.01) for the arteriolar den-
sity. Blood vessel profile areas per myocardial area
examined were 4900 ± 800 µm2/mm2 and 1550 ±
400 µm2/mm2 (p <0.01) respectively. Figures 1 and
2 illustrate the difference of vascular density be-
tween both groups. 
Figure 1
Factor VIII immunostaining of a sample of the control group
(image width = 0.8 mm).
Figure 2
Factor VIII immunostaining of a sample of the growth 
factor group (image width = 0.8 mm). Both arteriolar or
capillary densities are clearly increased when compared
with figure 1.
In this experimental model, bovine bone pro-
tein derived growth factors induced a significant
neovascularisation, composed of both capillary
and arteriolar structures, in healthy myocardium.
The idea for using bovine bone derived growth
factor mixture came from the important role of an-
giogenesis in bone formation, including fracture
healing [1] and endochondral ossification in the
growth plate [2]. Murine osteosarcoma derived
bone morphogenetic protein can induce ectopic
bone through the whole process of endochondral
bone formation. Yoshikawa et al. [3] have estab-
lished an experimental model of induction of bone
formation in which ectopic ossicles form repro-
ducibly within three weeks of implanting collagen
pellets containing bone morphogenetic protein
into the back muscles of mice. These ossicles have
been found to be highly vascular. In the same
model [4], daily subcutaneous administration of
TNP-470, a strong antiangiogenic agent, inhib-
ited ectopic new bone formation in a dose-de-
pendent manner. Histology revealed that TNP-
470 prevented proliferation of mesenchymal cells
and chondrogenesis at the initial step of endo-
chondral bone formation and that this process re-
sumed after discontinuing the TNP-470.
Individual growth factors have been shown to
play an essential part in bone formation. When de-
livered directly into a freshly created fracture in the
rabbit fibula, a single injection of bFGF and
hyaluronan results in the stimulation of callus for-
mation, increased bone formation and earlier
restoration of mechanical strength at the fracture
site [5]. Vascular endothelial growth factor
(VEGF) inactivation results in a complete disrup-
tion of the normal vascular pattern of the growth
plate of juvenile mice. Indeed, VEGF-mediated
blood vessel invasion is essential for coupling re-
sorption of cartilage with bone formation [6]. In
this study, in order to produce only angiogenic ef-
fects without induction of bone formation, bone
protein was injected in Povidone instead of sup-
plying the matrix which is required for bone for-
mation.
One potential advantage of using a mixture of
multiple growth factors derived from bone protein
lies in the fact that they may act synergistically.
Two in vitro study [7, 8] have demonstrated that
combined administration of VEGF and bFGF to
endothelial cell cultures in three-dimensional col-
lagen gels results in much greater and more rapid
capillary tubule formation than the additive effects
of either mitogen alone. Similar results were re-
ported in vivo with the combination of VEGF and
FGF [9] and that of SH/HGF and VEGF (scatter
factor/hepatocyte growth factor) [10] in a rabbit
model of hindlimb ischaemia. There is growing
evidence therefore, that combinations of growth
factors potentiate one another, and in that respect
bone protein growth factor mixture has the po-
tential to be a useful product even, perhaps, as a fu-
ture treatment strategy in patients with ischaemic
heart disease.
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